HRP20221034T1 - Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća - Google Patents
Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća Download PDFInfo
- Publication number
- HRP20221034T1 HRP20221034T1 HRP20221034TT HRP20221034T HRP20221034T1 HR P20221034 T1 HRP20221034 T1 HR P20221034T1 HR P20221034T T HRP20221034T T HR P20221034TT HR P20221034 T HRP20221034 T HR P20221034T HR P20221034 T1 HRP20221034 T1 HR P20221034T1
- Authority
- HR
- Croatia
- Prior art keywords
- aclidinium
- physical activity
- micrograms
- reduced
- daily life
- Prior art date
Links
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 title claims 28
- 229940019903 aclidinium Drugs 0.000 title claims 23
- 230000037081 physical activity Effects 0.000 title claims 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims 3
- 229960005012 aclidinium bromide Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 2
- 238000005265 energy consumption Methods 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Aklidinij ili bilo koji od njegovih stereoizomera ili mješavina stereoizomera, ili farmaceutski prihvatljiva sol ili solvat navedenog, za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća.
2. Aklidinij za upotrebu prema patentnom zahtjevu 1, gdje je aklidinij u obliku aklidinij bromida.
3. Aklidinij za upotrebu prema patentom zahtjevu 1 ili 2, gdje je aklidinij u obliku formulacije suhog praha pogodne za inhalaciju.
4. Aklidinij za upotrebu u formulaciji suhog praha prema patentnom zahtjevu 3, osigurava izmjerenu nominalnu dozu aklidinija ekvivalentnu od 100 do 1000 mikrograma aklidinij bromida po inhalaciji, poželjno 200 do 400 mikrograma aklidinij bromida.
5. Aklidinij za upotrebu u formulaciji suhog praha prema patentnom zahtjevu 3, koji osigurava izmjerenu nominalnu dozu aklidinija ekvivalentnu 400 mikrograma aklidinij bromida po inhalaciji i/ili izmjerenu nominalnu dozu od 343 mikrograma aklidinija po inhalaciji.
6. Aklidinij za upotrebu u formulaciji suhog praha prema patentnom zahtjevu 3, koji osigurava isporučenu dozu aklidinija ekvivalentnu 375 mikrograma aklidinij bromida po inhalaciji i/ili isporučenu dozu od 322 mikrograma aklidinija po inhalaciji.
7. Aklidinij za upotrebu prema bilo kojem prethodnom patentnom zahtjevu, gdje se aklidinij daje jednom ili više puta na dan, poželjno gdje se aklidinij daje dva puta dnevno.
8. Aklidinij za upotrebu prema bilo kojem prethodnom patentnom zahtjevu, gdje se aklidinij daje zajedno s terapijski djelotvornom količinom kortikosteroida, beta-adrenergičkog agonista i/ili inhibitora PDE4.
9. Aklidinij za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, gdje se fizička aktivnost u dnevnom životu povećava povećavanjem jednog ili više od sljedećeg:
a) prosječnog broja koraka po danu;
b) minuta umjerene aktivnosti po danu;
c) prosječne aktivne potrošnje energije; ili
d) nivoa fizičke aktivnosti.
10. Farmaceutski sastav koja obuhvaća aklidinij, kako je definirano u bilo kojem prethodnom patentnom zahtjevu, za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća.
11. Aklidinij za upotrebu kako je definirano u patentnom zahtjevu 1 ili 2 gdje pacijent pokazuje smanjenu fizičku aktivnost.
12. Aklidinij za upotrebu prema patentnom zahtjevu 11, gdje smanjena fizička aktivnost uključuje jedno ili više od sljedećeg:
a) smanjen prosječan broj koraka po danu;
b) smanjene minute umjerene aktivnosti po danu;
c) smanjena prosječnu aktivna potrošnju energije, ili
d) smanjen nivo fizičke aktivnosti (PAL).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382507 | 2012-12-17 | ||
| US201361750952P | 2013-01-10 | 2013-01-10 | |
| EP13805376.4A EP2931275B1 (en) | 2012-12-17 | 2013-12-13 | Aclidinium for use in increasing physical activity in daily life in a patient suffering from chronic obstructive pulmonary disease |
| PCT/EP2013/076606 WO2014095663A1 (en) | 2012-12-17 | 2013-12-13 | New use of aclidinium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221034T1 true HRP20221034T1 (hr) | 2022-11-11 |
Family
ID=47458806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221034TT HRP20221034T1 (hr) | 2012-12-17 | 2013-12-13 | Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20150328194A1 (hr) |
| EP (1) | EP2931275B1 (hr) |
| JP (1) | JP6346618B2 (hr) |
| KR (1) | KR20150096400A (hr) |
| CN (1) | CN104869996A (hr) |
| AR (1) | AR094063A1 (hr) |
| AU (1) | AU2013363837A1 (hr) |
| CA (1) | CA2892928A1 (hr) |
| DK (1) | DK2931275T3 (hr) |
| ES (1) | ES2917879T3 (hr) |
| HR (1) | HRP20221034T1 (hr) |
| HU (1) | HUE059569T2 (hr) |
| IL (1) | IL239245A0 (hr) |
| LT (1) | LT2931275T (hr) |
| PL (1) | PL2931275T3 (hr) |
| PT (1) | PT2931275T (hr) |
| RS (1) | RS63476B1 (hr) |
| SI (1) | SI2931275T1 (hr) |
| TW (1) | TW201427660A (hr) |
| UY (1) | UY35196A (hr) |
| WO (1) | WO2014095663A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69617431T2 (de) | 1995-06-21 | 2002-08-01 | Asta Medica Ag | Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| UA93031C2 (uk) | 2004-07-16 | 2011-01-10 | Алміралл, С.А. | Інгалятор для порошкових медикаментів, фармацевтичний порошковий картридж для використання з інгалятором та спосіб використання інгалятора |
| EP2100599A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
-
2013
- 2013-12-13 WO PCT/EP2013/076606 patent/WO2014095663A1/en active Application Filing
- 2013-12-13 HR HRP20221034TT patent/HRP20221034T1/hr unknown
- 2013-12-13 US US14/652,817 patent/US20150328194A1/en not_active Abandoned
- 2013-12-13 SI SI201331994T patent/SI2931275T1/sl unknown
- 2013-12-13 PL PL13805376.4T patent/PL2931275T3/pl unknown
- 2013-12-13 CN CN201380066242.4A patent/CN104869996A/zh active Pending
- 2013-12-13 KR KR1020157015515A patent/KR20150096400A/ko not_active Application Discontinuation
- 2013-12-13 PT PT138053764T patent/PT2931275T/pt unknown
- 2013-12-13 EP EP13805376.4A patent/EP2931275B1/en active Active
- 2013-12-13 DK DK13805376.4T patent/DK2931275T3/da active
- 2013-12-13 ES ES13805376T patent/ES2917879T3/es active Active
- 2013-12-13 LT LTEPPCT/EP2013/076606T patent/LT2931275T/lt unknown
- 2013-12-13 HU HUE13805376A patent/HUE059569T2/hu unknown
- 2013-12-13 AU AU2013363837A patent/AU2013363837A1/en not_active Abandoned
- 2013-12-13 RS RS20220736A patent/RS63476B1/sr unknown
- 2013-12-13 JP JP2015547055A patent/JP6346618B2/ja active Active
- 2013-12-13 CA CA2892928A patent/CA2892928A1/en not_active Abandoned
- 2013-12-17 AR ARP130104797A patent/AR094063A1/es unknown
- 2013-12-17 TW TW102146516A patent/TW201427660A/zh unknown
- 2013-12-17 UY UY0001035196A patent/UY35196A/es not_active Application Discontinuation
-
2015
- 2015-06-04 IL IL239245A patent/IL239245A0/en unknown
-
2016
- 2016-07-25 US US15/218,391 patent/US20160331733A1/en not_active Abandoned
-
2017
- 2017-02-17 US US15/436,178 patent/US20180000798A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2892928A1 (en) | 2014-06-26 |
| WO2014095663A1 (en) | 2014-06-26 |
| US20160331733A1 (en) | 2016-11-17 |
| AR094063A1 (es) | 2015-07-08 |
| AU2013363837A1 (en) | 2015-06-11 |
| CN104869996A (zh) | 2015-08-26 |
| ES2917879T3 (es) | 2022-07-12 |
| SI2931275T1 (sl) | 2022-07-29 |
| TW201427660A (zh) | 2014-07-16 |
| HUE059569T2 (hu) | 2022-11-28 |
| US20180000798A1 (en) | 2018-01-04 |
| RS63476B1 (sr) | 2022-08-31 |
| PT2931275T (pt) | 2022-06-30 |
| EP2931275A1 (en) | 2015-10-21 |
| EP2931275B1 (en) | 2022-06-01 |
| DK2931275T3 (da) | 2022-07-04 |
| US20150328194A1 (en) | 2015-11-19 |
| KR20150096400A (ko) | 2015-08-24 |
| LT2931275T (lt) | 2022-06-27 |
| UY35196A (es) | 2014-07-31 |
| IL239245A0 (en) | 2015-07-30 |
| JP2016502992A (ja) | 2016-02-01 |
| JP6346618B2 (ja) | 2018-06-20 |
| PL2931275T3 (pl) | 2022-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151214T1 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za lijeäśenje kroniäśne opstruktivne pluä†ne bolesti | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2011520911A5 (hr) | ||
| RU2014150422A (ru) | Новая дозировка и препаративная форма | |
| JP2007106777A5 (hr) | ||
| JP2015515475A5 (hr) | ||
| HRP20221325T1 (hr) | Pripravci i postupci transmukozne apsorpcije | |
| JP2011026348A5 (hr) | ||
| JP2016505023A5 (hr) | ||
| RU2016133305A (ru) | Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения | |
| EA201401354A1 (ru) | Новая дозированная форма и препарат, содержащий абедитерол | |
| JP2015519356A5 (hr) | ||
| HRP20221034T1 (hr) | Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća | |
| RU2013157398A (ru) | Композиция | |
| JP2014520874A5 (hr) | ||
| WO2011093815A3 (en) | Pharmaceutical compositions comprising formoterol and mometasone | |
| JP2011500731A5 (hr) | ||
| JP2013522295A5 (hr) | ||
| UA111123C2 (uk) | Застосування комбінованого терапевтичного засобу для лікування риніту | |
| JP2013542262A5 (hr) | ||
| WO2011093814A3 (en) | A pharmaceutical combination comprising formoterol and ciclesonide | |
| WO2011093812A3 (en) | Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form | |
| EA201591218A1 (ru) | Способы и композиции для введения оксибутинина | |
| WO2011093810A3 (en) | Dry powder pharmaceutical composition comprising tiotropium and mometasone | |
| PL406517A1 (pl) | Zastosowanie kwasu kynureninowego i jego soli oraz kompozycja farmaceutyczna |